In the third quarter of 2012 research and development expenses were $11.7 million dollars as compared to $10.8 million dollars for the same period of 2011. Third quarter general and administrative expenses were $2.8 million dollars as compared to $3.1 million dollars for the comparable period in 2011.
In the third quarter of 2012 the Company’s net loss was $15.0 million dollars or $0.25 cents per basic and diluted share as compared to a net loss of $12.7 million dollars or $0.26 cents per basic and diluted share in the same period of 2011.
As of September 30, 2012 the Company had approximately $55.1 million dollars of cash resources on hand. This includes net proceeds from the registered direct common stock offering to certain members of the Board of Directors in July 2012.
GuidanceThe Company expects to end 2012 with $38-$40 million in cash, cash equivalents and marketable securities. Based on our current operating levels we expect these cash resources will be sufficient to fund operations into the second half of 2013. These estimates assume no additional funding from new partnership agreements or equity financing events, and that the timing and nature of activities contemplated for 2013 will be conducted subject to the availability of sufficient financial resources. Conference call Management will conduct a conference call at 10:00 AM (EST) today to discuss clinical updates and third quarter financial results. The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investors" section of the Synta Pharmaceuticals website, www.syntapharma.com, prior to the event. The call can also be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. A replay will be available from 2:00 PM (EST) on November 6 through midnight (EST) on November 13. To access the replay, dial (877) 660-6853 or (201) 612-7415 and refer to conference ID 401666. The webcast will also be archived on the Company's website.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV